Literature DB >> 15221786

Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma.

Yun Wang1, Pedro Kringen, Gunnar B Kristensen, Ruth Holm, Mark M O Baekelandt, Magali Olivier, Hanne Skomedal, Pierre Hainaut, Claes G Tropé, Vera M Abeler, Jahn M Nesland, Anne-Lise Børresen-Dale, Aslaug Helland.   

Abstract

This study was conducted to evaluate the frequency and prognostic impact of TP53 alterations stratified for the TP53 codon 72 polymorphism (c.215G>C, p.Arg72Pro) in a cohort of 109 patients with advanced ovarian carcinomas. TP53 sequence variants were observed in 80 of the 109 (73.4%) tumors and were significantly associated with grade of differentiation (P=0.001). A tendency towards higher frequency of sequence variants in tumors with higher FIGO stages was seen (P=0.05). The type of TP53 sequence variant (transition A:T>G:C vs. G:C>A:T at CpG dinucleotides, and transversion G:C>T:A) had significant correlation with patients' age (P=0.04) with more A:T>G:C in patients over 60 years old. No significant associations were found between frequency of sequence variants and age at diagnosis, histological type, size of residual tumor after primary surgery, or long-term survival. Analyses of the codon 72 polymorphism in tumor DNA gave a higher frequency of homozygosity/hemizygosity than expected from the population frequency, particularly for the Pro allele. Tumors homozygous or hemizygous for the Pro allele had significantly higher frequency of TP53 sequence variants, particularly of the nonmissense type (P=0.002), and patients with these types of alterations had significantly shorter survival (P=0.04). TP53 protein accumulation, determined by immunohistochemistry (IHC), was found in 67.9% (74 out of 109) of the tumors, was significantly more common among serous than nonserous ovarian carcinomas (P=0.008), and had a significant effect on progression-free survival (P=0.03). p63 (TP73L; formerly TP63) and p73 (TP73) protein accumulation detected by IHC was seen in 67.9 and 0% of the tumors, respectively. A significantly higher frequency of p63-positive cases was seen among serous tumors (P=0.008) and tended to increase with increasing FIGO stages (P=0.05), but had no significant effect on survival. No association between p63 protein accumulation and TP53 protein accumulation was seen. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221786     DOI: 10.1002/humu.20055

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  15 in total

1.  Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk.

Authors:  Su-Qin Shen; De-Ke Jiang; Guo-Yuan Liu; Fang Chen; Long Yu
Journal:  Mol Biol Rep       Date:  2011-09-28       Impact factor: 2.316

Review 2.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

3.  Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population.

Authors:  S Mitra; S Banerjee; C Misra; R K Singh; A Roy; A Sengupta; C K Panda; S Roychoudhury
Journal:  J Clin Pathol       Date:  2006-11-01       Impact factor: 3.411

4.  Prognostic value of the TP53 Arg72Pro single-nucleotide polymorphism and susceptibility to medulloblastoma in a cohort of Brazilian patients.

Authors:  Raimundo M Carvalho; Giovanny R Pinto; France K N Yoshioka; Patrícia D L Lima; Carolina R T Souza; Adriana C Guimarães; Letícia M Lamarão; Juan A Rey; Rommel R Burbano
Journal:  J Neurooncol       Date:  2012-08-11       Impact factor: 4.130

5.  Association study between P53 and P73 gene polymorphisms and the sporadic late-onset form of Alzheimer's disease.

Authors:  Renato Scacchi; Giuseppe Gambina; Giuseppe Moretto; Rosa Maria Corbo
Journal:  J Neural Transm (Vienna)       Date:  2009-08-06       Impact factor: 3.575

6.  TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.

Authors:  Pedro Kringen; Yun Wang; Vanessa Dumeaux; Jahn M Nesland; Gunnar Kristensen; Anne-Lise Borresen-Dale; Anne Dorum
Journal:  BMC Cancer       Date:  2005-10-17       Impact factor: 4.430

7.  Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer.

Authors:  Heidi Lyng; Runar S Brøvig; Debbie H Svendsrud; Ruth Holm; Olav Kaalhus; Kjetil Knutstad; Halldis Oksefjell; Kolbein Sundfør; Gunnar B Kristensen; Trond Stokke
Journal:  BMC Genomics       Date:  2006-10-20       Impact factor: 3.969

8.  Mutation Analysis of TP53 Tumor Suppressor Gene in Colorectal Cancer in Patients from Iran (Kerman Province).

Authors:  Azadeh Lohrasbi Nejad; Mohammad Mehdi Yaghoobi
Journal:  Iran J Basic Med Sci       Date:  2012-01       Impact factor: 2.699

9.  High levels of genomic aberrations in serous ovarian cancers are associated with better survival.

Authors:  Lars O Baumbusch; Åslaug Helland; Yun Wang; Knut Liestøl; Marci E Schaner; Ruth Holm; Dariush Etemadmoghadam; Kathryn Alsop; Pat Brown; Gillian Mitchell; Sian Fereday; Anna DeFazio; David D L Bowtell; Gunnar B Kristensen; Ole Christian Lingjærde; Anne-Lise Børresen-Dale
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

Review 10.  Germline polymorphism of cancer susceptibility genes in gynecologic cancer.

Authors:  Masatsugu Ueda; Eisaku Toji; Osamu Nunobiki; Shinji Izuma; Yoshiaki Okamoto; Kiyo Torii; Sadamu Noda
Journal:  Hum Cell       Date:  2008-11       Impact factor: 4.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.